
CLAIMS

1. A compound of the formula:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the dose of Compound A to be administered to said subjects ranges from about 1 to 25 mg per day.

2. Compound A for use according to claim 1, wherein the dose of said compound to be administered to subjects in need thereof ranges from about 5 to 10 mg per day.


3. Compound A for use according to any of the previous claims, wherein the dose of said compound to be administered to subjects in need thereof is about 5 mg per day or about 10 mg per day.

4. Compound A for use according to any of the previous claims, wherein said compound is to be administered to subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

5. Compound A for use according to any of the previous claims, wherein said compound is to be administered to subjects in need thereof for at least one week, preferably at least three weeks.

6. Compound A according to any of the previous claims for use in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.

7. Use of a compound of the formula:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the dose of Compound A in the medicament ranges from about 1 to 25 mg per day.

8. The use according to claim 7, wherein the dose of said compound in the medicament ranges from about 5 to 10 mg per day.


9. The use according to claim 7 or 8, wherein the dose of said compound in the medicament is about 5 mg per day or about 10 mg per day.

10. The use according to any one of claims 7 to 9, wherein the medicament is to be administered to subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

11. The use according to any one of claims 7 to 10, wherein the medicament is to be administered to subjects in need thereof for at least one week, preferably at least three weeks.

12. The use according to any one of claims 7 to 11, wherein the medicament is for the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.

13~~7~~. Pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of the compound:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient.

~~8. Pharmaceutical composition for use according to claim 7~~, wherein the composition is to be administered orally to subjects need in thereof and wherein the dose of Compound A to be administered to said subjects ranges from about 1 to 25 mg per day.

14~~9~~. Pharmaceutical composition for use according to claim 13~~8~~, wherein the dose of Compound A to be administered to subjects in need thereof ranges from about 5 to 10 mg per day.

1510. Pharmaceutical composition for use according to claim 138 or 149, wherein the dose of Compound A to be administered to subjects in need thereof is about 5 mg per day or about 10 mg per day.

1611. Pharmaceutical composition for use according to any one of ~~the previous~~ claims 13 to 15, wherein the composition is to be administered to the subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

1712. Pharmaceutical composition for use according to any one of ~~the previous~~ claims 13 to 16, wherein the composition is to be administered to the subjects in need thereof for at least one week, preferably at least three weeks.

1813. Pharmaceutical composition for use according to any one of ~~the previous~~ claims 13 to 17, wherein the pharmaceutical composition is formulated as a single unit dosage form.


1914. Pharmaceutical composition according to claim 1813, wherein the single unit dosage form comprises about 1 to 25 mg, preferably about 5 to 10 mg of Compound A, optionally about 5 mg or about 10 mg of Compound A.

2015. Pharmaceutical composition for use according to any one of ~~the previous~~ claims 13 to 19, wherein the composition is formulated as a solid oral dosage form.

2116. Pharmaceutical composition for use ~~a~~ according to any one of ~~the previous~~ claims 13 to 20, wherein the composition is formulated as a tablet or capsule.

2217. Pharmaceutical composition according to any one of ~~the previous~~ claims 13 to 21, for use in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.

2318. Pharmaceutical composition comprising about 1 to 25 mg of the compound:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

24~~19~~. Pharmaceutical composition according to claim 23~~18~~, wherein the composition comprises about 5 to 10 mg of Compound A.

25~~20~~. Pharmaceutical composition according to claim 23~~18~~ or 24~~19~~, wherein the composition comprises about 5 mg of Compound A or about 10 mg of Compound A.


26~~21~~. Pharmaceutical composition according to any of the claims 23~~18~~-25~~20~~, wherein the composition is formulated as a single unit dosage form.

27~~22~~. Pharmaceutical composition according to any of the claims 23~~18~~-26~~21~~, wherein the composition is formulated as a liquid oral dosage form or as a solid oral dosage form, such as a tablet or capsule.

28~~23~~. Method for preparing a pharmaceutical composition according to any of the claims 23~~18~~-27~~22~~.

29. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of subjects suffering from or having an increased risk for cardiovascular

diseases, wherein the composition comprises a therapeutically effective amount of the compound:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient, wherein the medicament is to be administered orally to subjects need in thereof and wherein the dose of Compound A in the medicament ranges from about 1 to 25 mg per day.

30. The use according to claim 29, wherein the dose of Compound A in the medicament ranges from about 5 to 10 mg per day.

31. The use according to claim 29 or 30, wherein the dose of Compound A in the medicament is about 5 mg per day or about 10 mg per day.

32. The use according to any one of claims 29 to 31, wherein the medicament is to be administered to the subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

33. The use according to any one of claims 29 to 32, wherein the medicament is to be administered to the subjects in need thereof for at least one week, preferably at least three weeks.

34. The use according to any one of claims 29 to 33, wherein the medicament is formulated as a single unit dosage form.

35. The use according to claim 34, wherein the single unit dosage form comprises about 1 to 25 mg, preferably about 5 to 10 mg of Compound A, optionally about 5 mg or about 10 mg of Compound A.

36. The use according to any one of claims 29 to 35, wherein the medicament is formulated as a liquid oral dosage form or as a solid oral dosage form, such as a tablet or capsule.

37. The use according to any one of claims 29 to 37, wherein the medicament is for the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.